Dr. Youssef Bennani brings over 25 years of experience in pharmaceutical R&D leadership and management, with a track record of success spanning from project inception through to clinical work, technology transfer, and licensing transactions. He has played a key role in advancing over twenty preclinical and clinical-stage new molecular entities (NMEs) and has contributed to the development of approved medicines. His strategic governance leadership has been instrumental in driving corporate growth, particularly in guiding Domain Therapeutics and AdMare BioInnovations to the creation of nine single-asset and technology spin-off companies.

Dr. Bennani's previous leadership roles include serving as Chairman of the Board at Domain Therapeutics from 2014 to 2023 and as an independent Board Director at Bellus Health from 2014 to 2023, where he supported the company's successful acquisition by GSK in 2023. He was also the founding CEO of Find Therapeutics.

Earlier in his career, Dr. Bennani was the Site Head and Vice President of R&D at Vertex Pharmaceuticals Canada Inc., and served as Vice President of Drug Innovation at Vertex's headquarters in Boston, MA. He has held various senior roles in pharmaceutical R&D at Ligand Pharmaceuticals, Abbott Laboratories (now AbbVie), and Athersys. His work spans multiple therapeutic areas, including oncology, neurology, infectious diseases, inflammation, rare diseases, and renal diseases.

Dr. Bennani holds a PhD in Chemistry from Université de Montréal, an MBA from the Lake Forest Graduate School of Management (Chicago), and a Corporate Governance designation (ICD.D) from McGill University and Rotman School of Business.